Marksans Pharma Profit & Loss Annual

BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 | Sector: Biotechnology & Drugs

315.70 +7.15 (2.32%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	2,177.41	1,852.14	1,490.84	1,376.18
Total Revenue	2,177.41	1,852.14	1,490.84	1,376.18
Costof Revenue Total	1,038.12	921.36	748.02	618.60
Gross Profit	1,139.29	930.78	742.82	757.59
Selling/ General/ Admin Expenses Total	293.64	454.11	454.15	402.25
Depreciation/ Amortization	74.27	51.85	44.78	36.15
Other Operating Expenses Total	387.07	126.28	29.80	15.72
Total Operating Expense	1,793.10	1,553.60	1,276.74	1,072.72
Operating Income	384.31	298.54	214.10	303.46
Interest Inc( Exp) Net- Non- Op Total	-112.03	349.16	264.35	-10.33
Other Net	50.42	4.46	6.97	-0.30
Net Income Before Taxes	423.53	337.65	247.51	302.16
Provisionfor Income Taxes	108.63	72.33	60.70	63.63
Net Income After Taxes	314.90	265.32	186.81	238.54
Minority Interest	-1.20	0.99	-2.25	-2.60
Net Income Before Extra Items	313.70	266.31	184.57	235.94
Net Income	313.70	266.31	184.57	235.94
Income Availableto Com Excl Extra Ord	313.70	266.31	184.57	235.94
Income Availableto Com Incl Extra Ord	313.70	266.31	184.57	235.94
Diluted Net Income	313.70	266.31	184.57	235.94
Diluted Weighted Average Shares	45.33	41.54	40.93	40.93
Diluted EPS Excluding Extra Ord Items	6.92	6.41	4.51	5.76
DPS- Common Stock Primary Issue	0.60	0.50	0.25	0.25
Diluted Normalized EPS	6.92	6.42	4.51	5.88
Gain( Loss)on Saleof Assets	-	-2.64	0.00	0.30